Allentown, PA -- (SBWIRE) -- 10/08/2018 -- YMC America, Inc. is pleased to announce the release of their newest size exclusion chromatography column, YMC-SEC MAB. This silica-based SEC column uses a 3µm, 250Å dihydroxypropyl stationary phase which is bonded to a silica gel base, and is specifically designed to be used for antibody separations.

Utilizing a 250Å pore size, this material is well-suited for separating aggregates from monomer, but is also extremely effective at resolving lower molecular weight fragments. Offering high resolution and excellent peak shape over a broad range of molecular weight (10kDa to 700kDa), this material has been shown to work well for both characterization and quality control of antibody drugs. Additionally, YMC-SEC MAB provides excellent lot-to-lot reproducibility, making it an excellent choice for quality control methods.

This new SEC material exhibits low non-specific adsorption and has the ability to significantly improve accuracy on sizing analyses of monoclonal antibodies and other large proteins, including Antibody-Drug Conjugates (ADCs). When running sizing separations of ADCs, it is recommended to add organic solvent (typically ~15%) to the mobile phase in order to suppress any hydrophobic interactions from the higher drug-to-antibody (DAR) species and obtain optimal results.

Interested parties can view the full product specifications here.

Anyone looking to buy analytical columns, such as the new YMC-SEC MAB, or buy silica columns and other chromatography products, can visit YMC America, Inc.'s website at https://www.ymcamerica.com/ or call 888-341-8380 for additional information.

About YMC America, Inc.
YMC America, Inc. is a wholly-owned subsidiary of YMC Co. Ltd. (established in 1980). YMC America, Inc. sells and supports YMC liquid chromatography products and offers application assistance, purification services, and method development.

For more information about this global leader, visitors can browse https://www.ymcamerica.com/.